Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer

Abstract

Triple‐negative breast cancer (TNBC) develops from malignant cells within the interior lining of milk ducts or, less frequently, in the stromal tissues and accounts for around 15% of all breast cancers. Breast cancer is highly prevalent with the overall number of cases expected to reach 27.78 million by 2040, according to the World Health Organization (WHO). MiRNAs serve a novel role in management of breast cancer through their ability to indirectly control the translation of coding mRNA and regulate the expression of specific genes which allows it to play a significant role in cancer therapeutics. However, inherent characteristics of miRNA including rapid clearance via renal excretion, degradation by nucleases in plasma, and additional factors limit its clinical application. To reduce these limitations, miRNA can be administered in conjunction small molecules with nanocarriers which then allow it to impart its benefits including inhibition of epithelial‐mesenchymal transitions, and inhibiting tumor angiogenesis. This review highlights the current application of nanocarrier‐based delivery approach of miRNA/siRNA for triple negative breast cancer treatment.This article is protected by copyright. All rights reserved